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Abstract
Background: Pakistan is facing a threat from hepatitis C infection which is increasing at an alarming rate
throughout the country. More specific and sensitive screening assays are needed to timely and correctly diagnose
this infection.
Methods: After RNA extraction from specimen (HCV-3a), cDNA was synthesized that was used to amplify full
length core gene of HCV 3a. After verification through PCR, DNA sequencing and BLAST, a properly oriented
positive recombinant plasmid for core gene was digested with proper restriction enzymes to release the target
gene which was then inserted downstream of GST encoding DNA in the same open reading frame at proper
restriction sites in multiple cloning site of pGEX4t2 expression vector. Recombinant expression vector for each
gene was transformed in E. coli BL21 (DE3) and induced with IPTG for recombinant fusion protein production that
was then purified through affinity chromatography. Western blot and Enzyme Linked Immunosorbant Assay (ELISA)
were used to detect immuno-reactivity of the recombinant protein.
Results: The HCV core antigen produced in prokaryotic expression system was reactive and used to develop a
screening assay. After validating the positivity (100%) and negativity (100%) of in-house anti-HCV screening assay
through a standardized panel of 200 HCV positive and 200 HCV negative sera, a group of 120 serum specimens of
suspected HCV infection were subjected to comparative analysis of our method with commercially available assay.
The comparison confirmed that our method is more specific than the commercially available assays for HCV strains
circulating in this specific geographical region of the world and could thus be used for HCV screening in Pakistan.
Conclusion: In this study, we devised a screening assay after successful PCR amplification, isolation, sequencing,
expression and purification of core antigen of HCV genotype 3a. Our developed screening assay is more sensitive,
specific and reproducible than the commercially available screening assays in Pakistan.
Background
Hepatitis C is one of the most common liver diseases
around the world. It is caused by hepatitis C virus (HCV)
and a significant number of patients progress towards
chronic hepatitis, hepatocellular carcinoma (HCC) and
liver cirrhosis [1]. Viral infection is the major cause of
liver cirrhosis in about 20% of patients that after 10 years
lead to HCC in 3% of these patients per year [2]. The pre-
valence of HCV infection in various locations around
the world ranges from 0.5 to 10% [3]. Currently, almost
200 million people of the world population are infected
with HCV [4]. HCV genotypes and many subtypes have
been identified and are generally studied for epidemiol-
ogy, molecular diagnosis, development of vaccines, and
clinical management of the infection [5]. Still no vaccine
is available and the standard treatment is neither eco-
nomical nor fully effective in all the patients [6].
HCV is a positive single stranded RNA virus (Flaviviri-
dae family) [7,8] that is nearly 9.6 Kb in length having a
5’ non-coding region (5’NCR), a single open reading
frame (ORF) encoding a polyprotein of about 3,000
amino acids and a non-coding region at 3’ end (3’NCR).
The HCV polyprotein is postranslationally cleaved into at
least 3 structural (Core, E1 and E2) and 7 non-structural
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[9,10] and these proteins play important roles in virus
entry, replication, assembly, and pathogenesis through
host peptidase and viral protease activities [11].
Core gene is one of the most conserved regions of HCV
genome, involved in detection, quantitation [12] and geno-
typing [13,14]. It also interact with the envelop protein
(E1) and thus forms the HCV capsid [15]. The core anti-
gen-based assays has been reported to be helpful for the
measurement of HCV RNA among the patients under-
going dialysis [16] and shownt ob eu s e f u li n d i c a t o rf o r
HCV viremia in asymptomatic carriers [17]. It has also
been reported that the HCV core antigen-based methods
aree useful for the quantitative measurement of HCV with
respect to rapidness, easiness and low cost [12]. Moreover,
HCV core antigen-based assay can identify up to 94% of
viraemic donations given during the seronegative window
phase of infection. The performance of the assay appears
to be suitable for large-scale screening of blood donations
[18].
To combat and timely diagnose HCV, community based
serologic screening is of extreme significance due to dodgy
trend of asymptomatic nature of the HCV infection [18].
For this purpose rapid, economical, sensitive and more
specific assays are needed. The present work involved an
effort to design such an assay using purified HCV core
antigen from local isolates and to check out the opportu-
nity of these cloned HCV core gene to be further
employed in the possibility of vaccine development. We
also describe the application of recombinant HCV core
antigen from local isolates t of o r m u l a t em o r es p e c i f i c
screening assay for Pakistanip o p u l a t i o nw h e r eH C Vi s
becoming a big health problem.
Methods
PCR amplification, TA cloning and characterization of HCV
Core gene
The viral RNA was first reverse transcribed and then
used as template for polymerase chain reaction (PCR)
[19]. Full-length HCV Core gene (573-bp) [GenBank:
EU435145] was amplified with the following primers:
the forward primer (Core-F) 5’-GGATCCTGCAACAT-
GAGCACACTTCC -3’ containing the BamHI restriction
site and the reversed primer (Core-R) 5’-CTCGAGA-
GACGTGCCCGCCACTCT -3’ containing the XhoI
restriction site. The gel purified PCR product was then
ligated with T4 DNA ligase to yield the constructs. The
constructs were transformed into E. coli,a n dt h e
selected bacterial transformants were verified by restric-
tion enzyme analysis, colony PCR and sequencing.
Homology search
The DNA sequences of the core gene of HCV 3a
obtained were searched for homology with other
sequences in GenBank data base using blastn, at http://
www.ncbi.nlm.nih.gov/BLAST/. Different clones con-
structed in present study were aligned with the repre-
sentative HCV core gene sequences in the GenBank
database using Multalign software package. Pair wise
comparisons were performed to determine percent
nucleotide homology.
Sub-cloning and construction of recombinant expression
vector
Recombinant TA vector containing core cDNA of HCV
genotype 3a and expression vector pGEX4t2 (Invitrogen)
were digested with same restriction enzymes and ligated
by T4 DNA ligase (Fermentas-Life Sciences, USA) over-
night at 14°C, and stored at -20°C. The ligation product
was routinely transformed into Escherichia coli (E. coli )
DH5a by heat shock method and selected on LB broth
containing ampicilline (100 ug/ml). Then the recombi-
nant expression vector carrying target gene (pGEX4t2-C)
was transformed into E. coli BL21 (DE3) resulting in the
production of GST-C fusion protein.
Expression and purification
The positive individual clone was cultured in 5 mL
Luria bertani (LB) medium containing 100 μg/mL ampi-
cilline and then induced for 4 hours at 37°C, adding iso-
propyl-b-D-thiogalactoside (IPTG) at concentration of 1
mM. For IPTG dose optimization, the bacterial culture
was induced with different concentrations of IPTG [0.2,
0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0 (mM)] and allowed to
grow for 4 h at 37°C. For temperature optimization, the
bacterial culture was induced with IPTG [1.0 (mM)] and
allowed to grow for 4 h at three different temperatures
(25, 30 and 37°C). For time optimization, the bacterial
culture was induced with IPTG [1.0 (mM)] and allowed
to grow for 3 h, 4 h, 5 h and overnight (~16 h) at 37°C.
Total cell proteins from each optimization experiment
were analyzed by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE). Then, small-scale
expression was done by optimized conditions as
described above to prepare for purification [20]. The
protein amount was determined by Bradford assay using
bovine serum albumin (BSA) as previously described
[21].
The supernatant was then poured on to a purification
column and allowed to bind for 1 h with gentle shaking.
Finally, the proteins were collected and analyzed by
SDS-PAGE to assess the level of homogeneity. A 500 ml
induced bacterial culture (E.c o l iB L 2 1( D E 3 )w a sh a r -
vested after 4 h, centrifuged at 6000 × g for 10 min and
the cell pellet was suspended in 20 mM Tris buffer (pH
8.0). Different conditions like suitable liquid growth
media for E. coli, suitable growth temperature and pH,
IPTG final concentration for induction, post-induction
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mized. The cells were later lysed using lysozyme (0.1
mg/mL) at 4°C for 1 h and sonicated on ice for 5 min
at an amplitude of 30% with a 30 s pulse frequency. The
lysate was centrifuged at 10,000 × g for 20 min at 4°C
and the supernatant was collected as soluble fraction.
The resulting pellet was washed twice with 10 mL 2M
urea containing 50 mM Tris buffer (pH = 8.0), 1 mM
EDTA, 150 mM NaCl and 0.1% Triton X-100. The sus-
pension was centrifuged at 10,000 × g for 20 min at 4°C
and then the resulting subsidence was resuspended in
regeneration buffer containing 6 M urea, 0.5 M NaCl,
20 mM Tris-HCl (pH 7.9) and incubated at room tem-
perature for 30 min. The incubated mixtures were then
centrifuged at 10,000 × g for 20 min, and the superna-
tant was submitted to further purification.
After washing the column twice with 1X PBS, the
clear cell free lysate was loaded directly on GST-Fast
Flow Sepharose column (Amersham) with speed of 0.5
ml/min. Elution of the GST fusion protein complex was
done with 10 mM reduced glutathione prepared in 15
mM Tris-Cl (pH 8). Eluted fusion protein was dialyzed
in buffer containing 50 mM Tris-Cl pH 8 and 1 mM
EDTA for 4 hours. Peak fractions were analyzed by wes-
tern blot and ELISA.
Western blot
Western blot analysis of samples was carried out as
described previously [22]. In short, the proteins were
separated on a 10-12% separating gel and transferred to
nitrocellulose membrane electrophoretically. To prevent
non-specific binding, the membrane was blocked in
PBST (containing 0.5% Tween 20 and 2% BSA) blocking
buffer. Recombinant fusion protein was identified by
using rabbit polyclonal anti-GST antibody (Sigma) as
primary antibody and anti-rabbit horse radish peroxi-
dase conjugated antibody (Sigma) as secondary antibody.
Indirect ELISA
Enzyme linked immunosorbant assay (ELISA) was per-
formed by modifying the methods described previously
[23,24] (Engvall and Perlman, 1971; Lin et al. 2008). All
the values were represented by mean and standard
deviation (SD) as performance of the serological assays
is reported to be improved by adding 3 to 4 times the
SD to the mean OD value. For the comparison and ana-
lysis of different ELISA assays SD and coefficient of var-
iation (CV%) were used where needed.
HCV RNA PCR
HCV RNA qualitative PCR was done using SmartCy-
clerII Real-time PCR with kits from Sacace Biotechnolo-
gies, Italy as per procedure given in kit protocol.
Results
Expression and purification of recombinant core HCV 3a
antigen
The cloning strategy adapted for constructing the
recombinant plasmids is revealed in Figure 1. The
N-terminally GST-fused recombinant core protein was
produced in E. coli strain BL21 (DE3) with molecular
weight of about 46 kDa (Figure2 ) .T h eh i g h e s tl e v e lo f
expression was achieved in 2 × YT growth media (pH
7.5) at 25°C, with a 3 hours post-induction time, using
0.5 mM IPTG as an inducer. The strategy of our
research showed more promising results than other
eukaryotic systems or insect cell system because of its
less time consuming, high-level yield, convenience and
cost-effective. Finally, after the optimization of all condi-
tions for expression, we obtained 8.25 mg/500 ml of
protein from GST + Core construct.
Validation of recombinant core antigen as screening
agent
A standardized panel, established by the Division of Mole-
cular Virology, Center of Excellence in Molecular Biology,
consisting of 200 HCV negative and 200 HCV positive
specimens were tested by ELISA using the recombinant
structural core HCV 3a fusion protein and the anti-human
IgG conjugate. The results obtained after calculating the
means, standard deviations and co-efficient of variation
(CV %). Positive and negative results were differentiated
on the basis of cut-off value, which was calculated from
the arithmetic mean of sera negative for HCV infection
plus four randomly chosen standard deviations. Based on
this cut-off value (= 0.21), the results of anti-HCV screen-
ing assay were calculated as described previously [25].
Based on this value, all positive samples were found posi-
tive and all negative samples were found negative. Validat-
ing in-house anti-HCV screening assay via known sera,
100% positivity and negativity respectively were achieved.
In this connection, the present assay was analyzed by
classifying the HCV-positive and HCV-negative samples
into three groups each, and having them assayed three
times by the same person or by three different persons.
The coefficient of variations obtained from the intra-
person reproducibility for HCV positive and negative
sera were 4.88% and 5.88% respectively as shown in
Table 1. After validating and establishing the reproduci-
bility (Table 2) of present in-house anti-HCV screening
assay with known positive and negative sera, a total of
120 serum specimens of unknown results for HCV
infection were randomly collected representing almost
all geographical regions of Pakistan.
To detect HCV infection, samples were subjected to a
commercially available ELISA assay (following the man-
ufacturer’s protocol), ELISA assay validated in this study
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Comparative analysis of unknown sera by these three
assays is summarized in Table 3. Out of total 120 sera,
36 sera were positive by both our assay (sensitivity
100%) and PCR but one sample out of these 36 was
found negative by the commercial assay (sensitivity
97.2%).
Remaining 84 sera were negative by PCR, out of these
84 negative samples, our assay confirmed 83 (98.8%) as
negative but commercial assay gave false negative results
for 4 samples. It is demonstrated that in-house anti-HCV
screening assay has a high sensitivity, specificity and
reproducibility for detection of anti-HCV antibodies.
Discussion
Screening and diagnosing HCV is a key factor to treat
this infection as early as possible and to ensure the
Figure 1 Strategy of vector construction. (A) Scheme of the arrangement of HCV core gene in the expression vector pGEX4t2 that leads to
the construction of recombinant vector pGEX4t2C.
Figure 2 Western blot analysis of recombinant GST+C proteins
fusion complex. Lane M refers to the resolved pre-stained protein
marker, lanes 1- 2 to cell lysate of non-induced E. coli BL21 (DE3)
cells while lanes 3-6 refer to fusion complex of GST+E1 recombinant
proteins with a specific band of 46 kDa.
Table 1 Results of in-house anti-HCV screening assay
Mean Minimum Maximum S.D. CV%
Positive (n = 200) 0.82 0.58 0.91 0.051 6.21
Negative (n = 200) 0.17 0.09 0.18 0.012 6.66
Number of HCV positive and negative sera was 200 each. Cut-off value was
calculated 0.21. Samples exhibiting O.D. greater than 0.21 were considered
positive while those exhibiting less than 0.21 considered negative. Lower the
value of Coefficient of Variation (CV%) more authentic the results. Statistically,
CV% of maximum 10 is acceptable for the validation of the results. Coefficient
of Variation percentage is mostly affected by the extreme values in the data.
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at an alarming rate in Pakistan and 10% of the popula-
tion is already HCV infected and the rate is still ascend-
ing [26]. Imported kits are used for the screening of
HCV in Pakistan, however, these assays are associated
with two main concerns. First, the kits are not prepared
from the antigens representing local HCV strain owing
to this a considerable percentage of the suspected indivi-
duals are being given false results especially false nega-
tive. Secondly, Pakistan is poor country and cannot
afford precious foreign exchange that is being utilized as
a result of importing these HCV screening kits. More-
over, in routine healthy blood donors screening at blood
collection centers of developing countries like Pakistan,
rapid assay kit to screen HCV is erroneous because of
misleading results [27]. The asymptomatic nature of
HCV ‘The Silent Killer’ [28] is posing a serious threat to
Pakistani society.
In this study, we did isolate, cloned, characterized,
expressed and purified the full length core antigen of
Pakistani hepatitis C virus genotype 3a. The in vitro
antigenic activity of purified recombinant proteins paved
the way to develop an in-house anti-HCV screening
assay for the most prevalent HCV genotype (3a) in Paki-
stan. The main aim of our study was to evaluate core
antigen as anti-HCV screening agent and for that
purpose E. coli expression system was convenient. Het-
erogeneously expressed proteins in E. coli are widely
used for the development of screening assays for a num-
ber of diseases including HCV infection. Our research
findings shows more promised results than other eukar-
yotic systems and insect cell system as it is more effec-
tive, produces relatively high-level yield and convenient.
Further studies are needed, including elucidation of
more characteristics of the recombinant structural
fusion proteins and detection of anti-HCV antibodies in
human sera on large scale.
In several studies HCV core antigen based ELISA has
been used as a screening method for the identification
of HCV infection in human sera [29-31]. No screening
method has been developed so far in Pakistan based on
HCV types and isolates exist in this region and the sen-
sitivity and specificity of the commercially available
methods may be low for HCV strains common in Paki-
stan. Keeping in view these limitations of the available
assays, anti-HCV screening assay based on local HCV
isolates was developed and validated using recombinant
core antigen purified in the present study.
The HCV core antigen was first tested using 200 serum
samples with established HCV infection cases and 200
serum samples from anti-HCV and HCV RNA negative
sera to evaluate the sensitivity and specificity respectively
of the developed method. Detection of HCV RNA
through RealTime PCR was used as a reference to com-
pare and validate the results. The HCV core antigen and
the reference tests detected all 200 HCV positive samples
as positive and all 200 negative samples as negative. The
results are in accordance with the previous reports. A
report from Iran [32] described the expression of HCV
core antigen in E. coli but instead of ELISA, dot blot
assay was preferred to capture the antibodies in HCV
infected human sera. Important factors for a commercial
assay are its specificity and reproducibility. An assay
must yield concordant results when tests are repeated
[33]. In the present study, the assay was analyzed by clas-
sifying the HCV-positive and negative sera and con-
cluded that the reproducibility was sufficiently high.
To avoid false results, we used core antigen of HCV for
the most prevalent genotype (3a) in Pakistan. As com-
pared to ELISA, the rapid tests have not shown any pro-
mising results and hence should not be recommended in
transfusion centers for screening blood donors. More-
over, the failure of the rapid kits to detect HCV reactive
samples may be due to inadequate coating of the anti-
gens, heterogeneity of the virus nature of the antigens
used [34]. These evaluations focused on the working
characteristics of the present in house anti-HCV screen-
ing assay, such as ease of handling, specificity and sensi-
tivity on a group of well-characterized samples obtained
Table 2 Intra-person and inter-person reproducibility of
in-house anti-HCV screening assay
Intra-person
reproducibility
Inter-person
reproducibility
Anti-HCV Mean OD ± S.D CV (%) Mean OD ± S.D. CV (%)
Positive (n = 200) 0.860 ± 0.042 4.88 0.859 ± 0.051 5.93
Negative (n = 200) 0.17 ± 0.010 5.88 0.160 ± 0.011 6.87
Mean optical densities (OD), standard deviations (SD) and co-efficient of
variations (CV) of an established panel of HCV positive and negative sera are
shown depicting high reproducibity.
Table 3 Comparative analysis of in-house screening ELISA
assay, commercially available ELISA assay and HCV RNA
PCR as reference standard
Core antigen
assay
Commercial
assay
PCR
’Gold
Standard’
HCV true
positive
36 (100%) 35 (97.2%) 36
HCV true
negative
83 (98.8%) 80 (95.2%) 84
HCV false
positive
0 (0%) 1 (2.88%) 0
HCV false
negative
1 (1.2%) 4 (4.76%) 0
Total 120 120 120
Sensitivity of our assay and commercial assay was 100 and 97.2%, while
specificity was 98.8 and 95.2% respectively. The HCV RNA PCR was used as a
standard reference in the comparison.
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report their suitability for manipulation in small labora-
tories, i.e. blood collection centers. A possible drawback
of the present HCV core antigen based ELISA is that it
may not detect HCV infection in the sample taken prior
to the production of anti-HCV antibodies in the patients
i.e. the period between actual infection and production of
antibodies.
Conclusions
In the present study, we were able to obtain a high-level
expression of the recombinant HCV core antigen. In
this study, we devised a screening assay by using core
antigen of local HCV genotype 3a. This is the first
report of its own kind in which the core antigen of
HCV from a local strain was successfully used as screen-
ing agent. The sensitivity, specificity and reproducibility
of the developed assay is high than the commercially
available ELISA assays.
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